Daily BriefsMost Read

Most Read: Newcrest Mining, Gs Yuasa Corp, Cosmo Energy Holdings , Eoflow , Tuhu Car, LS Materials, Hollysys Automation Technologies, Medtronic Plc and more

In today’s briefing:

  • Newcrest/Newmont Conclusion Nearing – Flowfront & Gold Price
  • Solactive Global Lithium Index Rebalance: 45% Turnover & US$980m Trade
  • Cosmo Energy (5021) – Headed to an EGM Showdown for the Poison Pill
  • EOFLOW/Medtronic Tender: Closing Date Extended to 3 January 2024
  • HSCI Index Rebalance Preview: Tuhu Car in the Driver’s Seat; Keep Inc in the Running
  • Medtronic’s M&A of Eoflow Timeline Postponed
  • EOFlow Situation: Latest Disclosure, Market Speculations, & Key Short-Term Focus
  • LS Materials IPO Preview
  • Hollysys (HOLI US): MBO Proposal and Updates
  • EOFlow/Medtronic: Signs of Life


Newcrest/Newmont Conclusion Nearing – Flowfront & Gold Price

By Travis Lundy


Solactive Global Lithium Index Rebalance: 45% Turnover & US$980m Trade

By Brian Freitas

  • Solactive has announced the constituent changes for the Global Lithium Index. There are 8 adds and 9 deletes with implementation at the close on 31 October.
  • Estimated one-way turnover is in excess of 22% and will result in a one-way trade of US$490m. There are 11 stocks with estimated passive flows greater than 1x ADV.
  • The index is not very widely tracked and there could be big moves in stocks today and over the next few days – especially where there is multiple days ADV.

Cosmo Energy (5021) – Headed to an EGM Showdown for the Poison Pill

By Travis Lundy

  • Japanese activist Murakami-san and Cosmo Energy Holdings (5021 JP) have been duking it out for 18 months. He now has 20%. Wants more. Management wants to exercise the poison pill. 
  • Cosmo’s efforts are not completely honest, but Murakami-san’s efforts are clearly designed to benefit Murakami-san over general shareholders, and Cosmo has finally explained the reasons publicly. Read the doc (Japanese).
  • At 1.0x book, lower refining margins vs earlier in the year, and difficulty for Murakami-san to force the issue, one must take more care here than one did 40% ago.

EOFLOW/Medtronic Tender: Closing Date Extended to 3 January 2024

By Arun George

  • The closing date of the Eoflow (294090 KS)/Medtronic Plc (MDT US) transaction has been extended from 25 October 2023 to 3 January 2024. All other terms are unchanged.
  • The bull view is that despite the preliminary injunction and share suspension, Medtronic’s move underscores its commitment to the transaction on current terms.
  • The bear view is that the extension was Medtronic’s best move as it retains option value should Insulet’s lawsuit start floundering in court and KRX reinstate trading in Eoflow shares. 

HSCI Index Rebalance Preview: Tuhu Car in the Driver’s Seat; Keep Inc in the Running

By Brian Freitas

  • There were only 14 new listing on the Main Board of the HKEX (388 HK) in the third quarter. Half of the listings were in the last week of September.
  • Of those stocks, only Tuhu Car (9690 HK) and Keep (3650 HK) have a chance of being added to the HSCI in December and then into Southbound Stock Connect.
  • Keep Inc (3650 HK) could be added to Stock Connect in early December while Tuhu Car (9690 HK) will have to wait till April for inclusion to the link.

Medtronic’s M&A of Eoflow Timeline Postponed

By Douglas Kim

  • On 25 October, Eoflow announced that the M&A of Eoflow by Medtronic has been postponed. 
  • The closing date for Eoflow’s stock transfer agreement with Medtronic has now been changed to 3 January 2024. 
  • Although we believe Medtronic will continue to pursue Eoflow, the M&A tender offer price could be lowered to about 26,000 won, which would be nearly 20% higher than current price.

EOFlow Situation: Latest Disclosure, Market Speculations, & Key Short-Term Focus

By Sanghyun Park

  • We must acknowledge that the acquisition contract has not been withdrawn, signifying that we have averted the worst-case scenario.
  • During the shareholders’ meeting on November 15th, it is crucial for us to pay attention to whether personnel from Medtronic are included in the list of new board candidates.
  • If that’s the case, we can infer that Medtronic intends to go through with this deal, regardless of the litigation issues in the United States.

LS Materials IPO Preview

By Douglas Kim

  • LS Materials is getting ready to complete its IPO in Korea in late November. The IPO price range is from 4,400 won to 5,500 won per share. 
  • According to the bankers’ valuation, the expected market cap after the IPO is from 298 billion won to 372 billion won. 
  • LS Materials is one of the largest players globally in the large-size ultracapacitors, which stabilize power supply and are used to replace and supplement primary batteries and lithium-ion batteries.

Hollysys (HOLI US): MBO Proposal and Updates

By Arun George

  • Hollysys Automation Technologies (HOLI US) update notes a new MBO proposal at US$25 per share, a bidders shortlist in several weeks and an update on the special meeting. 
  • The update suggests several potential bidders and enough shareholders with the required record date to convene the special meeting to appoint independent directors. 
  • The MBO proposal, while potentially a delaying tactic, suggests that the Board are under pressure for a solution and is aiming for a friendly takeover. 

EOFlow/Medtronic: Signs of Life

By David Blennerhassett

  • When EOFlow (294090 KS) was suspended on the 11th October, and ceased global sales, either the Medtronic (MDT US) deal was (largely) toast; or it was a tactical move. 
  • I’m firmly in the latter camp. Insulet‘s lawsuit was expected. And completing the transaction enables the more financially and legally resource-rich MDT to become the party to the litigation.
  • The SPA between Jesse Kim and MDT was expected to complete on 25 October. That was not a hard date. It has now been pushed out to 3 January 2024. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars